In addition, CD96, CD244 have been identified as new checkpoint receptor targets for cancer immunotherapy [37, 38], and TGFβ1 has been found to play a key role in the EMT process in ccRCC [39]. This evidence concerns the gene CD244 and nonpapillary renal cell carcinoma.